Parkinson's Disease Clinical Trial
Official title:
Genetic Analysis of Parkinson's Disease
The purposes of this study are to identify the gene or genes responsible for an inherited
form of Parkinson's disease and learn more about how the disease develops.
In Parkinson's disease, a deficiency of a brain chemical called dopamine impairs the function
of the part of the brain that controls movement. As a result, patients may have difficulty
moving or they may have uncontrolled movements of their hands and fingers. Parkinson's
disease usually occurs sporadically, with no known cause. In a few families, however, the
disease seems to be inherited through a gene mutation (change). There is a 50-50 chance that
a parent with the mutated gene will pass it on to a child. Children who do inherit the
abnormal gene may or may not go on to actually develop Parkinson's disease-the relative
chance of this happening is not known.
Individuals 18 years of age and older from families in which Parkinson's disease appears to
be inherited may be eligible for this study. Participants will have a brief medical
examination, provide a personal and family medical history, and have a small blood sample (2
tablespoons) taken for genetic studies. The total time required for the study is about 1 to 2
hours.
Participants are encouraged to meet with a NIH investigator or with a genetics specialist in
their local area before testing to talk about the possible implications for themselves and
their families of the test results....
Individuals, and where possible multiple family members, from families with inherited
Parkinson's disease will be enrolled. We will also be enrolling people with sporadic
Parkinson's disease. Known disease genes will be sequenced to look for mutations. In the
event that no mutations are detected and there are samples from multiple family members,
linkage analysis will be undertaken in an effort to identify a region or regions of the
genome harboring defective genes that cause inherited Parkinson's disease. Candidate genes
that reside in regions linked to the disease will be sequenced in effort to find mutations
responsible for the disease.
Genetic linkage studies will include all available, informative family members, while gene
sequence analysis will be performed on affected individuals and spousal controls. In the
event that we identify a mutation of clear pathogenicity in one of the known Parkinson's
genes, we will contact all participating family members to notify them of the discovery of
the gene that causes PD in their family and offer them individual counseling and testing in a
CLIA approved lab. To assess any impact caused by the offer and subsequent pursuit of genetic
testing we will be administering a questionnaire assessing psychological well-being prior to
and following testing.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
| Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
| Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
| Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
| Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
| Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
| Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
| Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
| Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
| Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
| Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
| Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
| Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
| Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
| Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
| Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
| Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
| Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 |